Return to Clinical Studies
Clinical Studies
By Name
- ANG1005
- AS1411
- AVE0005
- AVE9633
- AZD4877
- Bevacizumab+ Sorafenib
- Bladder
- BSI-201
- BSI-201+different chemotherapeutic regimens
- C80405
- CALGB 90203
- CCI-779 (Temsirolimos)
- CDX110-003
- Clofarabine+ Cytarabine
- CNF 2024
- Colon
- CP-4055
- CT-322
- CX3543
- E2805
- E5597
- E7974
- EPO906A
- GT-111
- Hematological malignancies
- HKI-272 with PACLITAXEL
- HKI-272
- HSC20050377H
- huC242-DM4
- IBCSG-2 SOFT
- Investigator Initiated Trial
- LAPATINIB & CHEMOTHERAPY
- Liposomal Vinorelbine
- LP-261
- MBP-426
- MP470
- Non-Small Cell Lung Cancer
- NPI-2358
- NSABP PROTOCOL B-36
- NSABP PROTOCOL B-37
- NSABP PROTOCOL B-39 RTOG 0413
- NSABP PROTOCOL B-40
- NSABP PROTOCOL B-42
- ONTAK
- Ovarian
- PACCT-1 OR TAILORX
- Pegaspargase+ Gemcitabine
- PHA-793887
- PR11
- Pralatrexate
- Prostate
- PROTOCOL R-04
- PS341 (Velcade)
- PS341
- Quarfloxin (CX-3543)
- R0415
- R0522
- R0617
- R763
- Renal
- Reolysin
- RTOG 0513
- S-1 (Hepatic Dysfunction)
- S-1 (Renal Dysfunction)
- S0106
- S0325
- S0337
- S0354
- S0421
- S0429
- S0533
- S9346
- SSR97225
- STA-4783
- Suberoylanilide Hydroxamic Acid (SAHA)
- Tamibarotene
- TCN-PM
- Trastuzumab-DM1
- VA CSP 553
- XL 880-201
- XL 880-203
- XL820
- XL880 Phase II
- XL880
- XRP9881
- XRP9881+ Capecitabine
